Technology Catalysts has been interviewed and/or featured in a number of published articles over the years. To view these articles and other TCI press releases, please select a document from the list below:
Digital Health Challenges
November 01, 2016
TCI believes companies should be mindful of three main challenges regarding digital health before implementing these types of tools. These challenges include: patient and consumer challenges, provider implementation, and scaling up from pilot to commercial scale.
September 30, 2016
The gut contains trillions of “good” bacteria that play a major role in our health. Researchers now think that our gut microflora may be linked to a number of conditions ranging from digestive disorders, allergies, heart disease to depression. Probiotics are live microorganisms introduced into the body for their beneficial qualities. Probiotics have been used for many years and are conventionally incorporated into consumer goods and dietary supplements. An interesting area where the use of probiotics is being experimented is in drug delivery. Researchers are now investigating the use of microbes as drug delivery systems.
August 30, 2016
Indie beauty is one of the latest trends to hit the cosmetic retail market. It is defined as independently owned businesses that produce and provide products that have heart and soul – the types of product that have a true, personal meaning behind them, whether it is based on quality, passion, wellness, and/or sustainability.
June 09, 2016
With global sales forecasted to exceed $170 billion by 2021, oncology is by far the fastest growing therapeutic area. The current focus is on immuno-oncology (I-O) and especially the immune checkpoint inhibitors such as BMS’ Opdivo® and Merck’s Keytruda®. But what are the key strategies for long term success?
May 15, 2015
The Rx-to-OTC switch area is heating up and the market will continue to witness growth in the coming years.
May 01, 2015
Spurred by strong public interest, the FDA is actively reviewing guidance on the need for abuse deterrent formulations. The FDA is currently working on a case-by-case basis to determine whether or not opioid based formulations should only receive approval if they possess abuse deterrent properties.
July 01, 2014
Poor bioavailability is a major reason for compounds to fail in preclinical development. Technology Catalysts International (TCI) has compiled and analyzed technical and market information pertaining to the delivery of poorly water soluble or poorly permeable pharmaceutical compounds.
July 01, 2013
Consumer and scientific interest in the relationship between diet, health, and alternative medicines has created an increased demand for medical and modified functional foods. Sparked by rising interest in attaining wellness through diet, factors such as rapid advances in science and technology, increasing healthcare costs, changes in food labeling and claim regulations, and aging populations, have fueled the growth of both markets.